Promising Developments and Strong Financials Support Buy Rating for Alpha Tau Medical Ltd.

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Alpha Tau Medical Ltd and keeping the price target at $9.00.

Yi Chen’s rating is based on several promising developments at Alpha Tau Medical Ltd. The company is on the verge of initiating a U.S. pilot study for its Alpha DaRT technology in combination with first-line chemotherapy for pancreatic cancer, which is expected to start patient enrollment imminently. Additionally, a pilot study for recurrent glioblastoma multiforme is planned for later in the year, and the ongoing pivotal trial for recurrent cutaneous squamous cell carcinoma is progressing with patient recruitment expected to complete in the second half of 2025.
Further supporting the Buy rating is the company’s strong financial position, with $83.3 million in cash as of June 2025, and a recent successful direct offering that raised $36.9 million. The analyst also highlights potential catalysts, such as the expected response from Japan’s PMDA for pre-market approval in head and neck cancer and the operational start of a new facility in early 2026. The valuation of the company, based on a discounted cash flow analysis, suggests a price target of $9 per share, factoring in a 70% probability of approval in the U.S.

In another report released yesterday, Citi also maintained a Buy rating on the stock with a $8.00 price target.